news
FDA approves first biosimilar for the treatment of cancer
Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers…
List view / Grid view
Breast cancer
news
Taselisib boosts breast tumour shrinkage
According to results of the LORELEI clinical trial, adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer...
news
Z-endoxifen shows promise for breast cancer
Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer...
news
Immunotherapy combination effective at killing cancer cells
Researchers have recently discovered an immunotherapy that uses existing cancer drugs in a whole new way...
news
Metal simplifies synthesis of antibody drugs
Scientists have developed a method to efficiently modify natural antibodies that can deliver drugs to target cells...
news
Novartis receives EU approval for ribociclib
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
news
Cancer Research UK launches trial to test new drug
A clinical trial to test a new cancer drug in patients with advanced solid tumours, launches in four centres across the UK...
news
New imaging technique may predict the spread of breast cancer
Researchers have developed a new imaging technique to detect myeloid-derived suppressor cells’ accumulating in the lung...
news
Kadcyla new deal means NICE positive recommendation in draft guidance
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
news
SMC rejects Perjeta (pertuzumab) for NHS use for breast cancer
The Scottish Medicines Consortium (SMC) has made a final decision to turn down Perjeta (pertuzumab) for routine NHS funding for first line use in women whose HER2-positive breast cancer has returned to the breast but is inoperable, or where it has spread to other parts of the body.
news
Q BioMed to commercialise non-narcotic metastatic cancer pain drug
Q BioMed Inc has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.
news
Lynparza significantly reduces risk of disease worsening or death
8 June 2017 | By Niamh Marriott, Junior Editor
AstraZeneca's positive results from its trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival...
news
Biosimilar trastuzumab candidate shown similar in efficacy and safety
7 June 2017 | By Niamh Marriott, Junior Editor
Data has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab treatment in patients...
news
AstraZeneca Phase III breast cancer trial met primary endpoint
23 February 2017 | By Niamh Marriott, Digital Editor
AstraZeneca announced positive results from its Phase III trial comparing Lynparza to chemotherapy, to treat HER2-negative metastatic breast cancer...
news
Pfizer’s breast cancer drug too expensive for NHS
3 February 2017 | By Niamh Marriott, Digital Editor
NICE has today published draft guidance which does not recommend Pfizer's breast cancer drug palbociclib for routine funding on the NHS...
